Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stryker Ramps Up Compliance Spending, But Predicts Unimpeded Growth

This article was originally published in The Gray Sheet

Executive Summary

Stryker is raising its stake in compliance activities in response to government scrutiny of its regulatory and sales practices, but the firm does not foresee a major hit to its bottom line

You may also be interested in...



Ortho Earnings: Stryker Plans Big Compliance Investment In 2009

Stryker will spend between $60 million and $90 million on compliance initiatives in 2009, as it overhauls its quality standards and resolves issues related to three outstanding FDA warning letters

Ortho Earnings: Stryker Plans Big Compliance Investment In 2009

Stryker will spend between $60 million and $90 million on compliance initiatives in 2009, as it overhauls its quality standards and resolves issues related to three outstanding FDA warning letters

Biomet U.S. Hip Sales Advance 14% In Q1; Spine Revenues “Essentially Flat”

Biomet's accelerated U.S. hip sales growth of 14% for its most recent fiscal quarter is attributable in part to difficulties facing its competitors, as well as the strength of products like its Taperloc hip system, M2a-Magnum acetabular system and E-Poly acetabular liners, according to the company

Related Content

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel